Angiotensin has many different actions, most of which relate, either directly or indirectly, to the regulation of blood pressure, fluid, and electrolyte homeostasis (1, 2). In addition to potent vasoconstrictor effects, actions ofangiotensin on vasculature include the stimulation ofprostaglandin release (3), the modulation of angiotensin receptor number (4), and the stimulation of angiogenesis (5). Angiotensin also has important actions on the central and peripheral nervous systems, the adrenal, kidney, intestine, and heart (6-1 1). Given these multiple diverse actions of angiotensin, two important questions are (a) which of these actions represent normal physiological events, and (b) whether such actions may assume a pathogenic role. These questions have recently been placed in sharper focus by the clinical application of inhibitors of the renin-angiotensin system (RAS),' and in particular, the use of converting enzyme inhibitors (CEIs) for the treatment of hypertension. Any attempt to answer these questions requires an accurate concept ofthe RAS. The purpose ofthis review is to discuss new concepts concerning angiotensin production by the circulating RAS, how these relate to angiotensin production within tissues, and the possible mechanisms by which CEIs lower blood pressure. The study of tissue angiotensin systems is still at an early stage. In this review I have attempted to synthesize a coherent model of the interaction between the circulating and tissue angiotensin systems, which might assist in the interpretation of new developments in this area.
Recent evidence suggests that this classic concept of the circulating RAS requires revision (14, 15) . Given the extensive conversion of Al to All and clearance of both peptides across peripheral tissues, both Al and All are present in venous blood in amounts far too high to be explained by their generation in blood alone. Rather, the evidence suggests that the major site of production of Al and All is peripheral tissues (reviewed in reference 15). According to this revised concept, the primary function of the circulating RAS is not the systemic delivery of All to tissues, but rather the delivery of renin and angiotensinogen to tissues; most Al and All is generated locally within tissues by the action ofplasma-derived renin on plasma-derived angiotensinogen and the action of tissue converting enzyme. Thus, this revised concept predicts that plasma levels of angiotensin largely represent a spillover from the tissue sites of production (15) . That plasma angiotensins predominantly result from the action of kidney-derived renin on plasma (liver-derived) angiotensinogen is shown by the fall in plasma angiotensin levels that follows nephrectomy (16) (17) (18) (19) , and by the hypotensive effect of anti-angiotensinogen antibodies when injected into either sodium-replete or sodium-deplete rats (20) . Given this local production ofAl and All by the circulating RAS, it is apparent that such local production may be subject to tissue-specific mechanisms of regulation, which cause changes in local All concentration that are not reflected in the plasma concentrations of renin or All. Such tissue-specific mechanisms may include the extent of tissue uptake of renin and angiotensinogen, and the local tissue concentration of converting enzyme.
Tissue angiotensin systems An increasing number of studies suggest the existence of local angiotensin generating systems which operate, in whole or in part, independently of the circulating RAS. These have been described for brain (21) (22) (23) (24) (25) , kidney (26) (27) (28) (29) (30) (31) , adrenal (32) (33) (34) , testis (35) , and arterial wall (36, 37) . Angiotensinogen is the only known precursor of the angiotensin peptides; thus, definitive evidence for an independent tissue angiotensin system requires demonstration of local synthesis of angiotensinogen. Recently, angiotensinogen messenger RNA (mRNA) has been detected in 12 different extrahepatic tissues of the rat: kidney, brain, spinal cord, aorta, mesentery, adrenal, atria, lung, stomach, large intestine, spleen, and ovary (38, 39) . Renin mRNA has also been detected in several extrarenal tissues: adrenal, heart, testes, and submaxillary gland (40) (41) (42) . These data for extrarenal renin mRNA were obtained from studies of mice with two renin genes. These two renin genes have different patterns of tissue-specific expression, and for many tissues (adrenal, heart, testes) it is not known to which gene the renin mRNA corresponds; whether these data apply to man and other species with one renin gene remains to be determined.
The detection of mRNAs for angiotensinogen and renin in a tissue is strong evidence for their local synthesis in vivo. Evi-dence for local renin production is also provided by studies demonstrating renin synthesis in vitro by chorionic cells (43, 44) and by vascular tissue (45, 46) . However, given that the reninlike activity of aortic tissue falls to very low levels after nephrectomy (47, 48) , local synthesis would appear to make little contribution to vascular reninlike activity in vivo. In contrast to the obligatory role for angiotensinogen as angiotensin precursor, many different enzymes are able to cleave angiotensinogen to release AI or All. In addition to renin, enzymes that release AI include cathepsin D (49, 50) , pepsin (51) , and other aspartyl proteases (52) (53) (54) and reninlike enzymes (55) (56) (57) (58) . Enzymes that cleave angiotensinogen to release All directly include tonin (59) , cathepsin G (60), trypsin (61) , and kallikrein (62) . Thus, there would not appear to be an obligatory role for renin in local tissue angiotensin systems. Moreover, enzymes other than converting enzyme may convert Al to All (59, 63, 64) .
In man, as much as 90% of circulating renin is inactive (65) , and this inactive renin has a plasma half-life approximately twice that ofactive renin (66) . This inactive renin represents prorenin that was not completely processed by cleavage ofthe prosegment before secretion (67) (68) (69) . Although the kidney is an important site of synthesis of inactive renin (66) , the presence of nearly normal plasma levels of inactive renin in nephrectomized subjects (65, 66) (72) suggest a similar intracellular mechanism for local angiotensin production. However, these immunohistochemical studies need to be interpreted with caution because intracellular angiotensin-like immunoreactivity may represent any of several possible mechanisms: (a) Intracellular production of angiotensin from angiotensinogen synthesized within the same cell; (b) Intracellular production of angiotensin from angiotensinogen taken up by the cell; or (c) Angiotensin taken up by the cell. For the kidney, angiotensinlike immunoreactivity has been shown to coexist with reninlike immunoreactivity in juxtaglomerular cells (27, 28) , and isolated renin granules have been reported to contain AI and AII (31) . However, these renin granules may have been contaminated during isolation with angiotensinogen granules (30) , which have been identified in cells of the proximal tubule (73) . Immunohistochemical studies have not supported the proposal that juxtaglomerular cells synthesize angiotensinogen (29, 73) , and studies of colchicine-treated rats suggest that angiotensinogen in cells of the proximal tubule is not locally synthesized but represents angiotensinogen reabsorbed from the glomerular ultrafiltrate (73) Given that locally produced angiotensin may be derived from the interaction of plasma-derived renin and angiotensinogen, and/or the interaction of locally synthesized components, an important question is the relative contribution of these two systems to local angiotensin production. For those areas ofthe brain and spinal cord within the blood-brain barrier, locally synthesized components are probably the major source ofangiotensin. However, for other tissues, this question remains unanswered. Inasmuch as local production is the major source of plasma angiotensin, circulating renin and angiotensinogen are the major determinants of local production overall. This is shown by the response of plasma angiotensin to nephrectomy and the hypotensive effects of anti-angiotensinogen antibodies, cited above. However, the presence of reninlike activity and immunoreactive AI and All in the plasma of anephric subjects (16, 18, 19, 66, (74) (75) (76) , and the hypotensive response to the CEI, captopril, by a sodium-depleted anephric subject (77), suggest that renin or reninlike enzymes synthesized in extrarenal tissues may, in addition to local angiotensin production, also contribute to the generation of plasma angiotensin.
Estimates ofangiotensinogen mRNA abundance in liver and other tissues (38, 39) suggest that extrahepatic synthesis of angiotensinogen is unlikely to make a significant contribution to circulating levels ofangiotensinogen. However, synthesis of angiotensinogen by a tissue may cause a significant increase in the angiotensinogen concentration ofinterstitial fluid ofthat tissue. The concentration ofangiotensinogen in interstitial fluid is similar to that of plasma (78) (83) . However, several studies have found no increase in plasma bradykinin levels in response to the orally active CEIs captopril and enalapril (84-86), although there is some question as to the accuracy of the methods used to measure plasma bradykinin levels (87). Enalapril does not increase plasma prostaglandin E2 metabolite levels (86).
Both the kallikrein-kinin and the prostaglandin systems are best regarded as local tissue endocrine (paracrine) systems, somewhat analogous to the model of the RAS presented here (Fig. 1) . Indeed, CEIs do appear to modify kinin production at the local tissue level, as shown by the increase in urinary kinin excretion and also by the down-regulation ofuterine bradykinin receptors during captopril administration, accompanied by normal levels of circulating bradykinin (88) (89) (90) . The increase in renal kinin production may mediate the increase in renal production of prostaglandins that accompanies both captopril and enalapril administration (91) (92) (93) .
The relative contribution of prostaglandins in mediating the effects of CEIs may be dependent upon the sodium status, and thus the degree ofactivation ofthe RAS. The hypotensive effects of captopril in normal subjects on a high sodium diet, or in rats with deoxycorticosterone acetate/salt hypertension, can be blocked with inhibitors of prostaglandin production (94, 95) . In contrast, inhibitors of prostaglandin production do not modify the hypotensive effects of captopril in subjects on a low sodium diet, or in spontaneously hypertensive rats (94, 96) .
Administration of CEIs does inhibit All formation, and plasma All falls to undetectable levels (97). Many studies have shown less marked falls in plasma All (83) (84) (85) (86) 98) , but these results probably reflect methodological problems, including cross-reactivity by the elevated plasma levels of Al (99) , and also a significant assay blank (98) . The hypotensive effects of acute inhibition of All production may be due to inhibition of any of several All-dependent pressor mechanisms. These include the direct vasoconstrictor effects of All, the facilitation of adrenergic transmission by All (100) , and the effects of All on central sympathetic (101) and angiotensin (100) (102, 103) . At present, the relative importance of these mechanisms is unknown. The hypotensive effects of chronic inhibition of angiotensin production may also be due to inhibition of the effects of All on aldosterone secretion, and fluid and electrolyte transport in the intestine and kidney, in addition to inhibition of vasopressin secretion (104) and inhibition ofthe "slow pressor" effect of All (105) .
Attempts to directly demonstrate a nonangiotensin mechanism for the hypotensive actions of CEIs have met with mixed success. Textor et al. (106) observed no effect of captopril on the blood pressure of rats chronically infused with All. Studies comparing the hypotensive responses to saralasin (an All antagonist) and captopril have shown a greater response to captopril, and also an additional effect of captopril when given to saralasin-pretreated rats, thus suggesting a nonangiotensin mechanism for the effects of captopril (107, 108) . However, interpretation ofthese studies is complicated by the partial agonist activity of saralasin. Subsequent studies comparing renin inhibitors with CEls (109, 1 10) have, with one exception (1 11), not shown any discrepancy, and these data have been considered to indicate that the hypotensive response to CEIs is primarily mediated through inhibition of All formation. These studies were performed in sodium-deplete subjects, however, and whether these results apply to sodium-replete subjects will require further investigation.
Given the complexity of AII-dependent mechanisms, it is not yet possible to fully interpret the effects of CEIs in hypertension. Evidence that the hypotensive actions of renin inhibitors and CEls may be due, at least in part, to inhibition oflocal tissue angiotensin systems is reviewed elsewhere (15, 100) . While the effects ofCEls on the function ofa particular tissue may represent a reduction in local All levels, they may also be indirect, resulting from the interruption of other, possibly multiple, AII-dependent processes, such as a decrease in sympathetic nerve activity; moreover, CEI effects independent of the RAS may also contribute.
Concluding comments
Accumulating evidence indicates that the major site of angiotensin production is not in blood but in tissues, and results from the action of plasma-derived renin on plasma-derived angiotensinogen, together with the interaction of locally synthesized components. Both the production of angiotensin in tissues and the regulation of its production may be, to a greater or lesser extent, independent of the circulating RAS. This new concept of the RAS indicates a need to revise previous concepts concerning the role ofangiotensin in hypertension. The development ofthese concepts has been greatly accelerated by the availability of more specific inhibitors of All production and their therapeutic effectiveness in hypertension.
Our increasing knowledge of the RAS has revealed it to be much more complex than previously thought. One immediate challenge is to obtain a clearer insight into the mechanisms and regulation of angiotensin production in vivo, in individual tissues, and within the multiple compartments of each tissue, including the brain. The application of hybridization in situ to monitor cellular levels ofmRNA for renin and angiotensinogen will assist in this endeavor. However, there is also a need for the development ofmethodology able to measure the concentration of All at the local receptor level, if the functional and pathogenic significance oflocal tissue angiotensin systems is to be established.
